Genmab (GMAB) reported a 2025 net profit Tuesday of $15.37 per diluted share, down from $17.53 a year earlier.

Analysts polled by FactSet expected $18.48.

Revenue for the 12 months ended Dec. 31 was $3.72 billion, compared with $3.12 billion a year earlier.

Analysts surveyed by FactSet expected $3.70 billion.

For 2026, the company expects revenue in the range of $4.07 billion to $4.40 billion. Analysts polled by FactSet estimate $4.32 billion.

Shares of the company were up 1.5% in recent Tuesday trading.

Price: 30.53, Change: +0.50, Percent Change: +1.67